Index

Note: Page numbers in italic indicate Figures and those in bold indicate Tables.

3-D image analysis 53
four-compartment Petri dish technique 306
6-well plate technique 303–306, 305–306

a
acral areas, definition 389
acral vitiligo
anesthesia 392
approach to treatment 398
cell suspension transplantation technique 394, 395
characteristics of acral sites 389–391, 390, 391
choice of surgical procedure 391–392
definition of acral sites 389
dermabrasion of the recipient site 393–394, 394
difficult-to-treat sites 389–391, 390, 391
eyes 395
finger tips 395, 396–398
harvesting the skin graft 393
informed consent for the procedure 392
lips 395
management challenges 389
penis 395
post-procedure instructions 394
preoperative counseling 392
preoperative laboratory studies 392
preparation of autologous melanocyte cell suspensions 392–393, 393, 394
procedural modification for special acral areas 394–398
scrotum 395
surgical management 389–398
thin split-thickness skin grafting 245
tryptsinization and cell separation 393, 393, 394
acrofacial vitiligo
classification 35, 36
clinical features 37–38, 37
activity of vitiligo, biomarkers to predict 482–483
adalmimub 154
adaptive immunity, role in vitiligo 21–22
Addison's disease 16
adenomatous polyposis coli (APC) 10
adenylate cyclase (AC) 11
adipose tissue-derived stem cells (ADSCs) 179
Adjustment to Chronic Skin Disorders questionnaire 71
adrenocorticotropic hormone (ACTH) 10, 11
afamelanotide 5, 24, 98, 99–100, 143, 146, 146, 155–156, 436, 479
with phototherapy 441
Africa
current stigma about vitiligo 420–421
history of stigma of vitiligo 419
impact of cultural beliefs on treatment of vitiligo 421–422
age of onset of vitiligo 16
albinism 11, 412–413
Allsworth, Joyce 459, 460
alopecia areata 6, 16
alpha-lipoic acid 98, 99, 142, 144
alternative systems of medicine 159–168
alternative therapies 141–148, 142–143
amelanotic (inactive) melanocytes 27
Ammi majus 105
use in Ancient Egypt 174
Ammi visnaga 141
Ampligreffe meshing machine 258–259, 259
antioxidants 476
with phototherapy 441

© 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.
Companion website: www.wiley.com/go/Gupta/Vitiligo
antiseptics, leukoderma caused by 409
anxiety in vitiligo sufferers 70
apoptosis, induced in melanocytes 21
areola, thin split-thickness skin grafting 245
Asia
current stigma about vitiligo 420–421, 421
history of stigma of vitiligo 419
impact of cultural beliefs on treatment of vitiligo 421–422
atopic dermatitis 16
autoimmune disease, comorbidity with vitiligo 16–17, 429
autoimmune pathophysiology of vitiligo 15, 16, 20–21, 21, 125
future research directions 476–479, 477
autoimmune susceptibility genes 17
autologous, cultured epidermal cellular grafts 201–202
lip vitiligo 377–378
autologous, cultured melanocyte grafts 202
autologous melanocytes, transplantation 193–199
autologous, non-cultured epidermal cell suspensions 200–201
autophagy response to cellular stress 20, 21
axin 10
Ayurveda 159–166
description and treatment of vitiligo (switra) 159–160, 160, 161
dietary recommendations for vitiligo 163–166, 166
patient-centric drug selection 160–161
therapeutics for vitiligo 161–163, 164–165
three energy principles (doshas) 159–161, 160, 161
azathioprine 128
with phototherapy 442
B
Bactigrass® 259, 259
basal cell layer suspension transplantation 281–290
advantages 290
anesthesia of the recipient site 286
cell suspension applied to dermabraded lesions 282–283, 283
choice of treatment method 281
density of cells for transplantation 282
documentation 288
effectiveness 288–290
factors affecting outcome 288–290
follow-up evaluation 288, 288
methods 282–288
obtaining donor tissue 283–284, 284
premedication of the patient 286
release and preparation of free cells 284–286, 284, 285
transplantation and aftercare 286–288, 287
treatment of leukoderma 281–282
types of leukoderma 281–282
beard area, thin split-thickness skin grafting 244
Beck Depression Scale 70
β-catenin 10
betamethasone 86, 98
OMP therapy 125–126
bFGF (basic fibroblast growth factor) 11, 30
bFGF-derived peptide 147
bFGF gene 27
Biblical view of vitiligo 417–419, 418, 419
bimatoprost 143, 147
biologic therapies for vitiligo 151–156, 152
biomarkers to predict vitiligo activity and stability 482–483
BL-3-type laboratory 365
Blair–Brown grafts 241
Blake, Thomas 459
bleaching cream 470
Bolt’s procedure 466–467
bone morphogenic proteins (BMPs) 10
British Association of Skin Camouflage (BASC) 459
broadband (BB) UVA irradiation 110
burn injury, depigmentation caused by 249, 409
C
calcineurin inhibitors 5
topical treatments 134–136, 135
with phototherapy 441
calcipotriol 98–99, 98, 137–138
with phototherapy 440
calcitriol 98
camouflage, 435, 459–467
basic principles of skin camouflage 459–460, 460, 461, 461
classification 461–462
cosmetic camouflage application technique 463–464, 464
definition of skin camouflage 459
extraction of melanin from hair to prepare camouflage cream 466–467, 466
fixing powder or spray 462
formulations of cosmetic camouflage 462
history of skin camouflage 459
ingredients of cosmetic camouflage 462, 462
materials needed 463, 463
micropigmentation 204
popular commercial
foundations commonly
available 465
practice pearls for camouflage
application 463–464
pre-camouflage counseling
462–463
prevention of vitiligo exposure
on removal of camouflage
cream 465, 465
role in vitiligo 460–462
self tanning products 465, 465
use of henna 465, 465
uses for skin camouflage 459
cAMP (cyclic AMP) 10, 11
cAMP-responsive element binding
(CREB) proteins 10, 11
carbon dioxide (CO2) laser
351–352, 353
casein kinase Ia (CKIa) 10
CD4+ T cells 21, 22
CD8+ T cells 21–22, 82
CD25+ T cells 22
CD45RO+ cells 82
cell-based therapy, lip vitiligo 377
cell delivery on recipient skin
357–360
delivery techniques 357
methods and results 357–360, 358, 359
cellular autoimmunity 84, 86
cellular grafting techniques
199–203
cellular stress, role in vitiligo
19–21, 21
chemical leukoderma
409–410, 410
chemicals that induce or
exacerbate vitiligo 20, 21
childhood-onset vitiligo 16
quality of life issues 70
c-Kit ligand 10
classification of vitiligo 35–37, 36
segmental vitiligo on the face
41–42, 41, 42
segmental vitiligo on the trunk
42–43, 43
climatotherapy 64, 71
clinical features 35, 37–45
contact vitiligo 45
inflammatory vitiligo 44–45, 44
occupational vitiligo 45
rare variants of vitiligo 43–45
segmental vitiligo 39–43, 40
unclassified vitiligo 43
undetermined vitiligo 43
vitiligo/non-segmental
vitiligo 35, 37–39
cognitive behavioral therapy
(CBT) 64, 70–71
cold trypsinization 306, 307, 308
combination therapies for
vitiligo 24, 97–100, 98, 439–446
role in vitiligo treatment
444–445
with PUVA 107
COMET initiative 49
COMIS project 49
comorbidities associated with
vitiligo 16–17, 429
complementary and alternative
systems of medicine
(CAM) 159–168
cold therapy 463–464
cryotherapy
depigmentation 471
erdipression by 351, 352
CSG-COUSIN 49
CTL4A gene 17
cultural beliefs about vitiligo
417–419
impact on treatment and patient
perception of prognosis
421–422
cultured autologous melanocytes
323–334
abundance of
melanocytes 323–324
anesthesia of the recipient
site 329
applied to dermabraded
lesions 325
choice of treatment method for
leukoderma 323
cryopreservation 328–329
culturing of melanocytes
327–328, 328
defrosting of cells 329
documentation 331
donor tissue 325–326
effectiveness of the technique
332–334
follow-up evaluation 331, 332
location of melanocytes in
human skin 324, 324
methods 325–331
premedication of the
patient 329
release and preparation of free
cells 326–327, 326–327
transplantation and
aftercare 329–331, 330, 331
treatment of leukoderma
323–324
types of leukoderma 323–324
cultured melanocyte suspensions
177–178
CXCL9 21
CXCL10 21, 23, 129
CXCL10 blockers 152–153
CXCL11 21
CXCR3 21, 23
CXCR3 blockers 152–153
cyclic therapeutic paradigm of
therapy 430
cyclophosphamide 128–129
cytotoxic T lymphocytes 129
danger-associated molecular
patterns (DAMPs) 20–21, 21
Darier’s disease 24
Delnet® 286
dendrites of melanocytes 27, 28
dendritic cells 5
depigmentation
clinical characteristics 3, 4
considerations in choice of surgical therapy 249–250
examination under a Wood's lamp 3, 4
range of causes 249
see also leukoderma
depigmentation treatment for vitiligo 178, 469–472
decision to use depigmentation 469–470
implications for the patient 469
indications for 469
techniques 470–472
depigmented disorders, history of recognition and social stigma 174
depression in vitiligo sufferers 70
Dermabrador-Kurtin wire planing brushes 258, 259
dermabrasion, harvesting donor tissue by 309–310, 310–312
dermatography 451
Dermatology Life Quality Index (DLQI) 56, 63, 69–70, 71
dermatomes
invention of 174
motorised 249–256
ultra-thin epidermal sheet grafting 249–256
dexamethasone 87
OMP therapy 125–126
DHI-carboxylic acid (DHICA)-melanin 10, 11
diabetes mellitus 16
difficult-to-treat sites of vitiligo 389–391, 390, 391
diffuse repigmentation 29, 30
Digital Image Analysis System (DIAS) 52–53
dihydroxyindole (DHI)-melanin 10, 11
discoid lupus erythematosus (DLE) 412
disease activity measures 54–55
deshulled family proteins 10
disposable punches 212, 212
dopachrome tautomerase 11
dynein 11
e
EDN3 (endothelin-3) gene 27
EDNRB (endothelin receptor B) gene 27
electrosurgery 178
embryological development of melanocytes 10
endothelin-1 11, 30
endothelin-3 10
environmental factors in vitiligo susceptibility 17
epidemiology
segmental vitiligo 40
vitiligo 15–17
epidermal cell suspensions 177
methods 309–315
epidermal curettage technique (ECT) 178–179
epidermal grafting 176
epidermal sheets see ultra-thin grafts
epidermal transplantation 24
epidermis removal methods 351, 352
epithelial grafts see ultra-thin grafts
erbium:YAG (Er:YAG) laser 352
etanercept 154
ethnic issues in vitiligo
management 417–423
eumelanin 9, 10, 11
European Union, regulation of somatic cell therapies 363–364
Euroquol-5 instrument 63
evidence-based treatment outcomes 77–78
exchange grafts 174–175
excimer devices 115–119, 116
lamp 116, 117–118, 118
laser 115–117, 116, 118, 118, 435
excision and primary suturing 203–204
exosomes 20, 21
eyebrows, thin split-thickness skin grafting 244
eyelid vitiligo
acral vitiligo treatment modifications 395
surgical management 380–383, 381, 382, 383
thin split-thickness skin grafting 244, 245
f
facial distribution of segmental vitiligo, classification 41–42, 41, 42
family history of vitiligo 17
finger tips, acral vitiligo treatment modifications 395, 396–398
Fixomull® 284, 325
flip-top grafts 198
5-fluorouracil (5-FU) 142, 144, 442
focal vitiligo 410
classification 35–37, 36
long-lasting 43
folic acid, oral 434
fractional ablative carbon dioxide (CO2) laser 357–360
fractionated CO2 laser 352–353, 354
frizzled family cell surface receptors 10
full-thickness punch grafts (minigrafts) 196
full-thickness skin grafts 174, 241
future directions in vitiligo treatment 475–484
antioxidants 476
biomarkers to predict vitiligo activity and stability 482–483
combating melanocyte oxidative stress 476
maintaining repigmentation in vitiligo patches 481–482, 483
maintenance phototherapy 482
maintenance therapy with topical immunomodulators 482
melanocyte stem cells and vitiligo 475–476
stimulating melanocytes 479–481
surgical treatment advances 481
tackling autoimmunity 476–479, 477

Gas proteins 11
Gauthier’s classification 42
gender, influence on vitiligo incidence and prevalence 16
generalized vitiligo classification 35, 36, 36
clinical features 38
genes associated with vitiligo susceptibility 16–17, 22

generic factors in skin pigmentation disorders 12
genetic influences on melanogenesis 9
genetic polymorphisms, causes of differences skin pigmentation 9
genital vitiligo incidence 383–384
surgical management 383–385, 384, 385
genome-wide association studies 22
ginkgo biloba (maidenhair tree) 127, 142, 144–145, 435

glucocorticoids, topical treatments 133–134, 134
glycogen synthase kinsase-3b (GSK3b) 10
Good Clinical Practice (GCP) 366, 491

Good Manufacturing Practice (GMP) 364–365
Goulian–Weck skin graft knife 283–284, 284, 325, 325
Gp100 7
Griscelli syndrome 12
growth factor receptor-bound protein 2 (GRB2) 11
GZMB gene 22

hair depigmentation 6, 7
hair follicle
location of melanocytes 27
melanocyte populations 7
melanocyte stem cells 27
micrografting 178
outer root sheath cell suspension transplantation 294
presence of epidermal and melanocyte stem cells 293
role of melanocytes and stem cells in repigmentation 293
tissue grafts 199
transplantation for vitiligo 294
hairsty areas, thin split-thickness skin grafting 244
halo nevi 249, 410–411
Hann’s classification 41–42, 42
Hashimoto’s thyroiditis 16
Hermsky–Pudlak syndrome 412
HGF (hepatocyte growth factor) 10
HGF gene 27
history of vitiligo stigma in various cultures 417–419
HLA gene 17
HLA-A gene 22
HMB45 expression by melanocytes 9
homeopathy
approach to vitiligo treatment 166–167, 167
dietary recommendations for vitiligo 163–166, 166

homocysteine levels in vitiligo patients 84
hormonal influences on melanogenesis 9
human skin factors influencing differences in color 9
location of melanocytes 27
humoral autoimmunity 84–85, 86
hydroquinone creams, leukoderma caused by 409, 410

IFIH1 gene 22
IFN-γ (interferon gamma), anti-interferon-gamma therapeutic strategy 129
IFN-γ signaling pathway 20, 21–22, 22
targets for treatment 23
IFN-γ/CXCL10 signaling pathway 477
IFN-γ/CXCL10-CXCR3 axis, as a therapeutic target 151–152
IL-17 pathway 478
IL2RA gene 22
immunomodulators in vitiligo treatment 5, 125–129
maintenance therapy with topical immunomodulators 482
immunopathogenesis of vitiligo 5
immunosuppressives in vitiligo treatment 23, 125–129

in vitro culture of melanocyte-bearing epidermis 175
in vitro cultured cellular grafts, safety of 363–366
in vitro cultured epidermal grafts 337–348
advantages and challenges 345, 348
clinical applications 340
culture conditions for optimal M/K ratio 338, 340
in vitro cultured epidermal grafts (cont’d)

histologic examination of the regenerated epidermis 344, 345
indications for use 337–338
overall success rate in the literature 345, 346–347
postoperative management 344
preparation of the cell culture 338, 339
preparation of the receiving bed 342, 343, 344
quality control of cell cultures 340, 341, 342
selection of patients 342

in vitro cultures of epidermis with melanocytes 177–178
incidence of vitiligo, variations 15–16

India
National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) 366
regulatory agency 366
Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) 82
induced heat-shock protein 70 (HSP70) 20–21, 21
inducible heat shock protein 70 (iHSP70) 476
inflammation, role in vitiligo pathogenesis 20–21, 21
inflammatory bowel disease 16
inflammatory vitiligo, clinical features 44–45, 44
infliximab 154
informed consent 392, 491–493
ensuring valid consent 491
example of Declaration (Informed Consent) for treatment 492, 493
for clinical studies 491
prior to surgery 491
inheritance patterns of vitiligo 15, 17
innate immune activation 20–21, 21
integrated management of vitiligo 159–168
approach to vitiligo treatment 168
Ayrurveda 159–166
dietary recommendations for vitiligo 163–166, 166
homeopathy 163–167
interferon gamma see IFN-γ
intermediate-thickness skin grafts, definition 241
International Federation of Pigment Cell Societies (IFPCS) 49
international prevalence of vitiligo 15–16
internet resources for vitiligo patients 71, 72
interviews, patient evaluation and assessment 62
isomorphic response 54–55

j
JAK (janus kinase) 23
JAK inhibitors 153–155, 477–478
JAK-STAT signaling pathway 477–478

k
keratinocytes
role in melanogenesis 10
role in repigmentation 27, 28, 30
transfer of melanosomes to 9, 11–12, 12
Keyes punch 211, 212
khellin 110–111, 141, 142
with phototherapy 441–442
kinesin 11, 12
KIT signaling pathway 10, 11
Koebele phenomenon (KP) 5, 82, 85, 86, 175, 282, 409
in vitiligo 54–55
influence on surgical treatment results 188–189
subtypes 470
Koebnerization associated with tattoos 455
KUVA (khellin UVA) 110–111, 141, 142

l
laser-assisted techniques 178
laser dermabrasion, followed by phototherapy 442
laser therapies 5
abrasion in transplantation procedures 351–354
depigmentation 470–471
leukoderma caused by 409
latanoprost and phototherapy 441
leprosy
confusion of vitiligo with 174, 417–419, 418, 419
social stigma 417–419, 418, 419
leukoderma
surgical methods 407–413
types of 281–282, 407–413
see also depigmentation
leukoderma other than vitiligo vulgaris, surgical treatments 407–413
leukotrichia 40–41, 41
causes of white hair 401
definition 401
dermabrasion and ultra-thin split-thickness skin grafting 402
follicular unit extraction (FUE) and transplantation 402–403, 403
hair transplantation 403–404, 404
incidence 401
minigrafting 402
non-cultured epidermal cell suspension transplantation 402
repigmentation 179
suction blister grafting and systemic PUVA 402
surgical management 401–404
treatment 401
levamisole 88, 128
light therapy see phototherapy
lip vitiligo
acral vitiligo treatment modifications 395
anatomic considerations 371, 372
incidence 371–372
precipitating conditions 372
psychological effects of disfigurement 371
social stigma of depigmentation 371
surgical management 371–380
surgical procedures 372–380, 374
thin split-thickness skin grafting 245
types and presentations 372
localized vitiligo, classification 35–36, 36
long-term results of non-cultured epidermal cellular grafting 299–301, 300
Loo trephine 211, 212
low-dose medicine (LDM) 478–479
low-level laser therapy (LLLT) 118–119

m
MAPK (mitogen-activated protein kinase) 10, 11
marginal repigmentation 29, 30
marital difficulties in vitiligo patients 70
MART-1 7
expression by melanocytes 9
Mastisol® 284, 287, 325, 330
maxacalcitol 98
MC1R (melanocortin 1 receptor) signaling 10, 11
factors affecting 11
vitiligo risk alleles 22
MC1R gene SNPs, causes of differences in skin and hair phenotypes 9
McIndoe, Sir Archibald 459, 460
medical treatment 5
approaches 22, 23
combinations of treatments 444, 445, 446
combined with surgical treatment 443–444
medically induced repigmentation 28–30
melagenine (melagenina) 143, 145
melanin
distribution throughout the epidermis 9
eumelanin 9, 10, 11
melanogenesis 10–11, 10
pheomelanin 9, 10, 11
photoprotective capacity of different types 9
production by melanocytes 9
synthesis 10–12, 10, 12, 27
transport in melanosomes 9
types of 9, 10, 11
melanoblasts 7, 27, 28
embryological development 10
genes expressed by 10
melanocortins 11
melanocyte stem cells 7, 27
vitiligo and 475–476
melanocyte-stimulating hormone (MSH) 10, 11
MSH/cAMP signaling pathway 10
melanocyte stress, innate immune activation 20–21, 21
melanocyte transplantation 5, 7, 24
adverse effects reported 273–275, 274
complications 273–275
limitations 275–276
techniques 273
using needing micrografting 267–270
melanocytes
ability to migrate 30–31
abnormalities 19–20
absence of 323–324
amelanotic (inactive) type 27
dendrites of 27, 28
differentiation and migration 27–28, 28
embryological development 10
exosomes 20, 21
future research directions 479–481
genes expressed in the epidermis 9
in the hair follicle 7
induced apoptosis 21
KIT signaling pathway 10, 11
locations in human skin and hair follicles 9, 27, 324, 324
MC1R signaling 10, 11
melanogenesis 10–11, 10
melanotic (active) type 27
production of melanin 9
role in the pigmentary system 9
somatic mosaicism hypothesis 24
melanoma risk, relationship to vitiligo risk 22
melanophilin 12, 12
melanosomes
development and transportation 11–12, 12
distribution in different skin types 9
transfer to keratinocytes 27
transport of melanin 9
melanotic (active)
melanocytes 27
Mepitel® 286, 330
mesh grafts for vitiligo 257–260
advantages 260
donor site dressing 259
harvesting 258
historical background 257
indications for mesh grafting 260
instruments 258–258, 259
Index

mesh grafts for vitiligo (cont’d)
258–259, 259
meshing of the graft
258–259, 259
placement and dressing of the
graft 259
postoperative care 259
preoperative preparation 258
preoperative work-up 258
principal of mesh grafting 258
procedure 258–259, 259
surgical treatments for
vitiligo 257–258
technique 258–259

methotrexate (MTX) 87, 127–128
8-methoxypsoralen
(8-MOP) 105
methylprednisolone 87
microneedling for cell
delivery 357–360, 358, 359
micropigmentation 204, 451–456
adverse effects and limitations
455–456
basic principles 451
definition 451
equipment and
procedure 452–453, 452, 453, 454
factors affecting cosmetic
results 454
history of tattooing 451
lip vitiligo 378–379, 379
pigments and
preparations 452
role in vitiligo
management 456
use in vitiligo and other
discoloration conditions
453, 455
minigrafting (miniature punch
grafting) 30–31, 82,
174–175, 176–177, 196,
211–221
advantages and
disadvantages 221
analysis of the technique 216,
218, 219–220, 220, 221
appearance of repigmentation
(AOR) time 220, 220
complications 216, 219, 219
development of surgical
methods 211
effectiveness 216, 218
evolution of mini-punch
grafting 212
follow-up and course of
events 214, 216, 216, 217,
218, 219
historical perspective 211
instruments required 213, 213
lip vitiligo 376, 376, 377
maximum pigment
spread 220, 221
movement of melanocytes 218
procedure 213–214, 213,
214, 215
punch instruments
211–212, 212
relapse after grafting
219–220, 220
stability of repigmentation
219–220, 220
test grafting 212–213
minocycline 88, 128, 143,
147, 479
minoxidil 143, 145
MITF (microphthalmia-associated
transcription factor)
expression 9, 10, 10, 11
MITF gene 10, 11, 27
mixed type vitiligo
classification 35–37, 36
clinical features 38–39, 39
MMPs (matrix
metalloproteinases) 28
monobenzone, ability to induce
vitiligo 20
monochromatic excimer light
(MEL) technologies
115–119, 116–118
MSH (melanocyte-stimulating
hormone) 10, 11
MSH/cAMP signaling
pathway 10
mucosal vitiligo
classification 35, 36
clinical features 38, 38
long-lasting 43
multi-chromatic, incoherent
light-based technology
113–115
multichrome vitiligo 43–44, 44
multiple sclerosis 16–17
myasthenia gravis 17
myosin Va (MYOVA) protein
12, 12
NALP1 gene 17
nanotechnology 478
narrow-band ultraviolet B
(NB-UVB) phototherapy
24, 71, 87, 93–100, 178
administration 94, 94
combination therapies
97–100, 98
contraindications 94–95
effects on oxidative stress 127
efficacy and prognostic factors
as monotherapy in
vitiligo 95, 96
home NB-UVB
phototherapy 93
immunomodulation and
repigmentation 126–127
light sources and lamps 93
mechanism of action in
vitiligo 95
persistence of repigmentation
after treatment 97
prognostic factors of
response 97, 97
role of phototherapy in vitiligo
treatment 93
safety profile 100
selectively permeable
sunscreen 143, 147
National Apex Committee for
Stem Cell Research and
Therapy (NAC-SCRT),
India 366
needling, therapeutic needling
technique 270
needling micrografting 179
needling micrografting for
melanocyte transplantation
267–270
advantages 270
effectiveness of the technique 270
follow-up and evaluation 268
glue and dressing 268
instruments 267–268, 268
preparation of the recipient area 267
preparation of the donor area 267
results 268, 269–270, 270
transplant technique 267–268

nevus anemicus 411–412
nevus depigmentosus 411
NGF (nerve growth factor) gene 27
NK (natural killer) cells 20, 21, 22
NLRP1 gene 22
non-cultured cellular grafting four-compartment Petri dish technique 306
6-well plate technique 303–306, 305–306
cold trypsinization 306, 307, 308
ReCell® kit 303, 304
simplified techniques 303–308
non-cultured epidermal cell suspension
harvesting donor tissue by dermabrasion 309–310, 310–312
in vivo preparation from suction blister graft 312–314, 312–314
lip vitiligo 378
novel preparation methods 309–315
preliminary results 315, 315
non-cultured epidermal cellular grafting, long-term results 299–301, 300
non-cultured extracted follicle outer root sheath cell suspension transplantation 293–297
advantages 297
development of the method 294

advantages 270
disadvantages 297
harvesting of grafts (follicular unit extraction) 294
instrumentation and laboratory ware requirements 294
preparation of NCEF ORS suspension and transplantation 294–296, 295, 296
results reported in various studies 296–297
role of hair follicle melanocytes and stem cells in repigmentation 293
technique 294–296, 295, 296
non-cultured extracted hair follicle suspensions 202–203
non-segmental vitiligo, classification 35–37, 36
North America
current stigma about vitiligo 420, 421
history of stigma of vitiligo 417–419, 418, 419
impact of cultural beliefs on treatment of vitiligo 421–422

O
OCA2 vitiligo risk alleles 22
occupational vitiligo, clinical features 45
oculocutaneous albinism 11, 412–413
O’Leary, Lydia 459, 460
OMP therapy see oral mini pulse therapy
oral corticosteroids 86–87, 98, 125–126
oral folic acid and vitamin B12 434
oral mini pulse (OMP) therapy 86–87, 125–126
oral vitamin D 434
outcome measures 49–57
challenges of defining 49–50
defining treatment goals 77–79
disease activity 54–55
quality of life (QoL) 55–57
repigmentation 50–54
oxidative stress combating 476
effects of NB-UVB 127
influence on stability of vitiligo 83–84, 86
role in vitiligo 19–21, 21

P
Padgett dermatome 258
Padgett grafts 241
pathogenesis of vitiligo 19–24
autoimmune activation 20–21, 21
chemicals that induce vitiligo 20, 21
genetic factors 22
innate immune activation 20–21, 21
melanocyte abnormalities 19–20
relationship to treatment approach 22, 22
role of adaptive immunity 21–22
role of cellular stress 19–21, 21
role of inflammation 20–21, 21
theories of 19
treatment targets 19
patient-centered outcome measures 77–78
patient communication approach to 73
counseling on realistic expectations 73–74
patient compliance relationship with the physician 72–73
strategies to improve 73
patient education need for 69–70
resources for patients with vitiligo 71, 72
patient evaluation and expectation assessment 62–63
patient satisfaction
perspective on treatment success 78
relationship with the physician 72–73
patient selection criteria, for autologous melanocyte transplantation 187–189, 188
patient support
need for 69–70
quality of life (QoL) interventions 70–71
patient trust 72–73
PAX3 (paired-box 3) gene 27
PAX3a expression by melanoblasts 10
pediatric vitiligo 427–436
general health issues in patients with vitiligo 430
incidence 427
issues for children 427–428, 428
issues with drugs and other treatments 430–436, 431–432
psychological aspects 427–428
penis, acral vitiligo treatment modifications 395
pentachrome vitiligo 43
perifollicular repigmentation 28–30, 29, 293
peripheral achromic halo 5, 6
pernicious anemia 16
phenol derivatives, leukoderma caused by 409–410, 410
pheomelanin 9, 10, 11
Photocil® 479–480
photodynamic therapy (PDT) 119
photoprotection, capacity of different types of melanin 9
phototherapy 5, 435
combined with medical treatment 439–442
combined with surgical treatment 443–444
controlled sun exposure 422–423
future directions 480–481, 482
maintenance phototherapy 482
role in vitiligo treatment 93
targeted phototherapy in vitiligo 113–119
UVA-based phototherapy 105–111
see also narrow-band ultraviolet B (NB-UVB)
physician approach to caring for vitiligo patients 74
perspective on treatment success 78–79
physician–patient relationship 72–73
piebaldism 249, 323–324
description 408
 genetic factors 408
in vitro cultured epidermal grafts 337–348
surgical treatments 408
pigmentary system 9
pimecrolimus 97–98, 98
topical treatment 134–136, 135
with phototherapy 440
pinta, confusion of vitiligo with 174
Piper nigrum (black pepper) 148
piperine 148
placental extract and phototherapy 442
pmel17 gene expression 11
point counting method 52
Polypodium leucotomos 98, 99
with phototherapy 441
postoperative information, cellular grafting 190
prednisolone 86
pregnant vitiligo patient autoimmune disorders associated with vitiligo 429
avoidance of consanguinity 429–430
disease course 429
general health issues in patients with vitiligo 430
health implications for the mother 428, 428
heritability of vitiligo 429–430
impact of vitiligo 427–430
issues with drugs and other treatments 430–436, 431–432
preventive strategies for vitiligo 429–430
premelanosomes 11, 12
prevalence of vitiligo, variations 15–16
preventive strategies for vitiligo 429–430
proinflammatory cytokines 11, 20, 21
prostaglandin analogs 5
prostaglandins and phototherapy 441
protein kinase A (PKA) 10, 11
pseudocatalase 145
Psoralea corylifolia Linnaeus 105
psoralen photochemotherapy see PUVA
psoralens 87, 105, 174
psoriasis 16
treatment goals example 77–78
psycho-education 63–64
psychological effects of vitiligo 72–73
psycho-neuro-endocrine immunology (PNEI) network 478
psychosocial burden of vitiligo 3, 61–65
aspects of the burden 61–62
climatotherapy 64
cognitive behavior therapy (CBT) 64
management 63–64
modifying behavior towards illness 64
patient evaluation and expectation assessment 62–63
psycho-education 63–64
reasons for assessment 61
support groups and organizations 65
psychosocial interventions in vitiligo 70–71
psychosocial morbidity in vitiligo 69–70
PTPN22 gene 17
punch instruments 211–212, 212
PUVA (psoralen photochemotherapy) 105–1010
PUVA (psoralen phototherapy) 105–1010
combination therapy 107
contraindications 106
history 105
immunomodulation and repigmentation 126
mechanism of action 105
oral PUVA 106–107
pre-treatment assessment and selection of patients 105–106
psoralens 87, 105, 174
PUVA-sol 109–110
repigmentation 28–29, 106
response dependent on anatomical site affected 106
side effects 108–109
topical PUVA 107
PUVA-sol 109–110

q
Q-switched laser technology 470–471
quadrichrome vitiligo 43
quality assurance system 365–366
quality of life (QoL) impairment in vitiligo 69–70
interventions 70–71
measures 55–57
QoL instruments 63

r
RAB27A gene expression 11
RAB27A protein 12, 12
rare variants of vitiligo 36
clinical features 43–45
Ras-MAPK pathway 10, 11
reactive oxygen species (ROS) generation in response to UV radiation 9
levels in vitiligo patients 20
ReCell cell harvesting device 200–201
ReCell® kit 303, 304
reflectance confocal microscopy 83, 86
repigmentation 27–31
color matching 31
initiation and activation 27–28
leukotrichia 179
maintaining 481–482, 483
medically induced 28–30
melanocyte migration 30–31
outcome measures 50–54
patterns of 28–30, 29
role of hair follicle melanocytes and stem cells 293
role of keratinocytes 27, 28, 30
stability of 31
stability of disease and 7
surgically induced 30–31
research on vitiligo, comparison with psoriasis research 3–5, 4
rheumatoid arthritis 17
rituximab 143, 146–147
ruxolitinib 153–154
safety of in vitro–cultured cellular grafts 363–366
cell-culture procedures 365
Good Clinical Practice (GCP) 366
Indian regulatory agency 366
quality assurance system 365–366
regulatory environment 363–364
source and characterization of materials and reagents 365
SCF (stem cell factor) 10, 10, 11, 27,475–476
SCF gene 27
scleroderma 16
scrotum, acral vitiligo treatment modifications 395
seed grafts 197–198
segmental vitiligo classification 35–37, 36
classification of distribution on the trunk 42–43, 43
classification of facial distribution 41–42, 41, 42
clinical features 39–43, 40
description 407
epidemiology 40
hair involvement 40–41, 41
incidence 407
mechanism 40
site of involvement 40–41
surgical treatments 407–408
selective sunscreen 479–480
selectively permeable for NB-UVB sunscreen 143, 147
Self-Assessed Vitiligo Extent Score (SA-VES) 51
Self-Assessed Vitiligo Scoring Index (SAVASI) 51–52
sequential activation kinetics (SKA) 478
sexual function, negative effects of vitiligo 70
SF-36 (Short Form-36) 57, 63
SHC (Src homology 2 domain-containing transforming protein 1) 11
SHP2 (SH2 domain-containing protein tyrosinase phosphatase) 11
Shweta Association 65
side effects of treatment 73–74
signaling pathways of melanogenesis 10–11, 10
simplified non-cultured cellular grafting 303–308
simvastatin 128, 129
single nucleotide polymorphisms (SNPs), causes of differences in skin pigmentation 9
Sjögren’s syndrome 17
skin bleaching products 409, 410
skin grafting
  basic principles and
  biology 241–242
development of surgical
  repigmentation methods
  175–179
during the Renaissance and
  beyond 173–174
ey early attempts 174–175
  harvesting 'pure' epidermal
  grafts 225
history of 173–174
  in ancient times 173
postoperative information
  for patients 185, 186–187, 190
split-thickness skin grafts
  173–174
  stability of vitiligo 175
types of tissue graft for
  vitiligo 194, 196

skin pigmentation disorders,
genetic factors 12

skin punch instruments
  211–212, 212

Skindex 63

smash grafting 179, 197–198, 261–265
  advantages and
  disadvantages 265
application of the graft
  262–263, 263
complications 263, 265
cost considerations 261
definition 261
effectiveness of the
  technique 261
harvesting the donor tissue
  262, 262
method 261–262
  patient selection 261
preparation of the recipient
  site 262
  preparation of the smash
  graft 262, 263
results 263, 264
  simplicity of the technique 261
social stigma associated with
  vitiligo 3, 417–423

  current social stigmas
  419–421
  evolution of 174
  history of 417–419
somatic cell therapy (SCT), safety
  regulation 363–366
somatic mosaicism
  hypothesis 24
SOS (son of sevenless) 11
SOX10 (sex-determining region
  Y-box 10) gene 27
SOX10 expression by
  melanoblasts 10
split-thickness skin grafts
  173–174, 197–198
  definition 241
  history of development 241
  stability of vitiligo 81–88, 86
  biochemical features and
  83, 86
  biomarkers to predict
  482–483
  clinical features and
  82–83, 86
  definition 81
  immunity and activity of
  vitiligo 84–85, 86
  microscopic features and
  84, 86
  monitoring 81–82
  oxidative stress and
  83–84, 86
  phenotype stability 7
  reflectance confocal microscopy
  and 83, 86
  skin grafting and 175
  ultrastructural features
  and 84, 86
  stabilization therapies 86–88
  standards and regulations 317
  STAT signaling 129
  STAT1 23
  statins 128, 478
  stem cell factor see SCF
  steroid treatment 5, 5
Streptomyces hygroscopicus var.
  ascomycetus 135
Streptomyces tsukubaensis
  134–135

  suction blister epidermal
  grafting 31, 174, 198–199,
  225–237
  advantages and
  limitations 234, 236–237
  chemical epilation on hair-
  bearing recipient-site
  skin 232
  course of grafts 232–233
dermabrasion of the recipient
  site 230–231, 231
dressing after grafting
  232, 232
efficacy and safety of epidermal
  grafting 233–234, 233, 234,
  235, 236
  harvesting the grafts 230
  hepatitis virus transmission
  risk 230
  HIV transmission risk 230
  laser ablation of the recipient
  site 231
  liquid nitrogen-induced
  blistering of the recipient
  site 231
  phototoxic blistering of the
  recipient site 232
  preparation of the recipient
  site 230–232
  separation of epidermis from
  dermis 225–230, 226–229
  suction blistering of the
  recipient site 231
  suction blistering technique
  225–230, 226–229
  transfer of grafts 232
  lip vitiligo 373, 375, 375
in vivo preparation of non-
  cultured epidermal cell
  suspension 312–314, 312–314

sun protection in vitiligo
  patients
  considerations 422–423
  cultural issues 417–419

sunscreen
  selective sunscreen 479–480
  selectively permeable for NB-
  UVB 143, 147
support groups and organizations 65, 71
surgical punch instruments 211–212, 212
surgical treatment 5
approaches 24
choice of surgical intervention 185
classification 193–204, 194
combined with medical treatment 443–444
combined with NB-UVB 100
combined with phototherapy 442–443
contraindications 189
development of repigmentation methods 175–179
future directions 481
history of development 173–179
induced repigmentation 30–31
leukoderma other than vitiligo vulgaris 407–413
leukotrichia 401–404
lip vitiligo 379–380
motivation and expectations of the patient 189
patient age and 189
patient information (postoperative) 185, 186–187, 190
patient information (preoperative) 185, 186–187, 189
patient information for the day of surgery 189
patient selection 185
patient selection for autologous melanocyte transplantation 187–189, 188
systemic immunomodulators 5, 125–129
systemic lupus erythematosus (SLE) 16, 412
systemic steroids therapy 5, 5
T helper 17 (Th17) cells 5
T helper 17 cell/IL-17 axis 478
T regulatory cells (Tregs) 22
tacalcitol 98, 98, 137–138
with phototherapy 440
tacrolimus 97–98, 98
topical treatment 134–136, 135
with phototherapy 440
targeted phototherapy in vitiligo 113–119
advantages 113, 114
limitations of conventional phototherapy 113, 114
technologies 113–119, 114
tattooing
lip vitiligo 378–379
see also micropigmentation
tattoos, leukoderma following laser removal 409
4-TBP (4-tert-butylphenol), ability to induce vitiligo 20
Tegaderm™ 284, 286–287, 325, 330
temporary camouflage 461–462
tetrahydrocurcuminoid cream with phototherapy 441
therapeutic needling technique 270
therapeutic wounding 203
thick split-thickness skin grafts 241
Thiersch grafts 174
Thiersch–Ollier grafts 197, 214
thin dermo-epidermal grafts 175–176
thin skin grafts for vitiligo 241–247
thin split-thickness skin grafting 174
acral areas 245
advantages and limitations 246–247, 246
adverse effects 245–246, 245
areola 245
basic principles and biology of skin grafting 241–242
beard area 244
biological changes which follow 241–242
course of the graft 245–246, 245
definition 241
eyebrows 244
eyelids 244, 245
hairy areas 244
harvesting the graft 242–243, 243
lips 245, 376–377
methods 242–245
modifications at ‘difficult-to-treat’ sites 244–245
patient selection considerations 242
postoperative care and follow-up 244
preparing the recipient area 243–244
thyroid disease, comorbidity with vitiligo 16
TICAM1 gene 22
tissue culture laboratory 317–321
alarm systems for devices 320
back-up power generators 320
biosafety cabinets (BSCs) 318–319, 319
centrifuges 320
electrical freezers 320
equipment 318–320, 319
incubators 319–320
laboratory design 317–318, 318, 318
liquid nitrogen 320
specialized devices for multiparametric analysis of single cells 320–321
standards and regulations 317
tissue grafts, types of 194, 196
TNF-α (tumor necrosis factor-alpha) 21
anti-TNF-α treatment 129
TNF-α inhibitors 154–155, 478
tofacitinib 153
tofacitinib citrate 128
topical treatments  133–138
corticosteroids  433
trichloroacetic acid (TCA) skin peeling, leukoderma caused by  410
trichrome vitiligo  43–44, 44
ultra-thin epidermal sheet grafting  advantages and limitations  256
ultra-thin skin grafts  197, 241–247
ultraviolet radiation  see UV radiation
unclassified vitiligo  36, 37
clinical features  43
undetermined vitiligo  36, 37
clinical features  43
unfolded protein response (UPR)  20
United States, regulation of somatic cell therapies  364
universal vitiligo classification  35, 36
clinical features  38
UV radiation effects on different types of melanin  9
generation of reactive oxygen species (ROS)  9
influence on MC1R expression  11
influence on melanogenesis  9
UVA-based phototherapy  105–111
UVA1 phototherapy  110
UVB phototherapy  5
see also narrow-band ultraviolet B (NB-UVB) phototherapy
vitamin B12 levels in vitiligo patients  84
oral  434
vitamin D oral  434
topical  434
vitamin D3 analogs, topical treatments  98–99, 98, 137–138
Vitiligo Area Scoring Index (VASI)  50, 81
Vitiligo Disease Activity (VIDA) score  54, 82, 175
Vitiligo European Task Force Assessment (VETFa)  50–51, 81
Vitiligo Extent Score (VES)  51
Vitiligo Friends support group  65
Vitiligo Impact Patient Scale (VIPS)  56–57
Vitiligo Impact Scale (VIS)  56
Vitiligo Impact Scale-22 (Vis-22)  56
Vitiligo Noticeability Scale (VNS)  52, 78, 79
Vitiligo Potential Repigmentation Index (VPRI)  53–54
vitiligo risk, relationship to melanoma risk  22
Vitiligo Society, The  65

...
Vitiligo-specific Health-related Quality-of-Life Instrument (VitiQol) 56, 63
Vitiligo Support International 65
vitiligo susceptibility factors 17
vitiligo vulgaris 35–37, 36
VLQI scale 63

**W**
Waardenburg's syndrome dermatological presentation 408
description 408
genetic factors 408
treatment 408–409
Western Europe, current stigma about vitiligo 420
history of stigma of vitiligo 417–419, 418, 419
impact of cultural beliefs on treatment of vitiligo 421–422
white hair see leukotrichia
WHOQOL 63
Willingness-To-Pay (WTP) Scale 57, 63
Wnt signaling pathway 10, 479
women, social stigma of vitiligo 3
Wood's lamp 3, 4

**X**
XBPI gene 22

**Z**
Zimmer® air-driven ultra-dermatome 252, 252
zinc supplementation 127